Jul 31, 2026 · 7 min
Apple slides on supply constraints while Amazon surges on cloud growth
Apple Slides Most Since 2025, Amazon Soars, Novo
Varying corporate earnings reports highlight how supply chain vulnerabilities and cloud infrastructure demands are reshaping market leadership.
- 1Apple shares fell to their lowest point in sixteen months after supply chain constraints weakened the company's sales forecast.
- 2Amazon stock surged on the back of accelerating cloud-computing revenue growth from its Amazon Web Services division.
- 3Novo Nordisk suffered a major setback when its experimental cardiovascular drug failed a critical late-stage clinical trial.
Don't miss
The breakdown of Novo Nordisk's unexpected late-stage clinical trial failure and its immediate impact on the pharmaceutical market.
The brief
A split-screen day on Wall Street reveals contrasting fortunes for tech giants, as supply chain bottlenecks drag Apple down while Amazon surges ahead on the strength of its cloud computing infrastructure.
Apple shares suffered their steepest decline in sixteen months after issuing a lackluster revenue forecast, signaling that hardware supply constraints are actively limiting the company's near-term growth.
Amazon countered the market gloom with a massive stock rally, driven by accelerating revenue growth at AWS as enterprise demand for cloud computing and artificial intelligence continues to scale.
Away from big tech, Danish pharmaceutical giant Novo Nordisk faced its own setback, watching its stock tumble after an experimental cardiovascular drug failed to meet expectations in a late-stage clinical trial.
What was said on this episode
9 statements · 5 positive · 4 negative
Apple’s revenue guidance disappointed investors because growth is forecast below expectations.
“Investors are really punishing the company here for a lackluster revenue guidance forecast to rise 9 to 11% in the fourth fiscal quarter anal expecting 12%.”
Listen at 1:14
Apple generated $32 billion in free cash flow.
“Let's not forget $32 billion in free cash flow.”
Listen at 2:59
Amazon led the Magnificent Seven year to date after rising about 15% in one day.
“Amazon has topped, has claimed that top SP but up about 17% year to date with today's move, of course they are up 15% just today in its largest rally since April 2012 on a closing basis.”
Listen at 3:20
Amazon’s US revenue grew nearly 40%, exceeding $40 billion.
“Revenue here jumped nearly 40% more than 40 billion at US which generates a fifth of the company's revenue.”
Listen at 3:42
Amazon’s cloud business accelerated growth for the fifth consecutive quarter.
“the cloud posted accelerating growth here for a fifth straight quarter.”
Listen at 4:00
Amazon’s increased capital-expenditure plans are paying off.
“this big Capex plans which they've also boosted for the new year are paying off.”
Listen at 4:09
Novo Nordisk’s experimental drug failed to reduce heart-attack risk in a large study.
“experimental drug failed to reduce the risk of heart attacks.”
Listen at 4:40
Novo Nordisk’s drug reduced its target protein without producing clinical significance.
“The shot reduced the protein that it was targeting but did not translate into clinical significance.”
Listen at 4:45
The failed drug study harms Novo Nordisk’s diversification effort beyond obesity and diabetes.
“This is a real blow for this company as it's trying to diversify away from obesity and the diabetes space where it's been the pioneer.”
Listen at 4:51
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
Apple Inc.
Amazon.com, Inc.
Novo NordiskListen to the full episode and explore every guest, topic, and moment on PodLume.